All terms
Quality-Adjusted Life Year
Outcome metric combining length and quality of life used in HTA.
Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026
Definition
A QALY equals one year of life in perfect health. HTA bodies use cost-per-QALY thresholds (NICE: £20–30K) to judge cost-effectiveness. The U.S. ICER applies similar methodology informally. What the regulation says
While QALYs are not directly regulatory requirements for safety or efficacy, they are crucial in the context of health technology assessment (HTA) bodies, which influence market access and reimbursement decisions for MedTech products. For example, the National Institute for Health and Care Excellence (NICE) in the United Kingdom uses QALY thresholds to evaluate the cost-effectiveness of medical technologies and interventions, impacting their recommendations for adoption within the National Health Service.
What this means in practice
Widely used outside the U.S. The U.S. has restricted use of QALYs in Medicare coverage decisions for certain age and disability populations.Examples
- A pharmaceutical company submits a new cancer drug for HTA review, where its efficacy data is translated into increased life years and quality of life, which are then used to calculate its cost-per-QALY.
- A medical device manufacturer developing an innovative prosthetic limb must demonstrate not only its functional benefits but also its cost-effectiveness, often expressed in terms of QALYs, to secure favorable reimbursement from national health systems.
- A diagnostic company seeking to introduce a novel screening test needs to show that the health improvements and extended life years resulting from earlier diagnosis, relative to the test's cost, provide a favorable QALY outcome.
Common pitfalls
- •A common pitfall is misunderstanding that QALYs are a direct measure of MedTech quality or safety, rather than an economic metric for cost-effectiveness.
- •Failing to consider regional differences in QALY thresholds and their impact on market access strategies can lead to significant commercial challenges.
- •Misinterpreting the U.S. restrictions on QALY use for certain populations in Medicare decisions can result in ineffective reimbursement strategies.
- •Assuming that a product with clinical benefits will automatically achieve positive QALY assessment without considering its cost implications is a frequent mistake.
Frequently asked questions
QALYs are used by HTA bodies to determine the cost-effectiveness of a MedTech product; a favorable cost-per-QALY ratio often correlates with positive reimbursement recommendations, influencing market access.
Related terms
Grouped by themeEditor's picks
· Hand-selected related conceptsMore in Reimbursement
· Same categoryReimbursement
340B Drug Pricing Program(340B)
Federal program providing discounted drugs to safety-net providers.
Reimbursement
Ambulatory Payment Classification(APC)
The Medicare grouping system that determines hospital outpatient payment amounts under OPPS, analogous to MS-DRGs for inpatient.
Reimbursement
ASC Site-of-Service Shift
Migration of procedures from hospitals to ambulatory surgery centers.
Reimbursement
Budget Impact Model(BIM)
Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.
Primary references
3 sourcesLink health: 3 verified· last checked 2026-06-20
NICE·1AdvaMed·1AMA·1
- 1
NICE methods manualVerifiedNICEnice.org.uk
- 2
AdvaMed - Payment & CoverageVerifiedAdvaMedadvamed.org
- 3
AMA CPT ResourcesVerifiedAMAama-assn.org
Inline markers like [1] jump to the matching reference above.